We keep getting asked the same question: if we use general-purpose AI tools to support a regulatory submission, will the output stand up to a regulator, a payer, or a notified body?
Every day, medical affairs, HEOR, and regulatory teams conduct literature reviews that support regulatory submissions, health technology assessment (HTA) dossiers, and post-market surveillance reports. These reviews are legally and scientifically accountable controlled documents on which product approvals, reimbursement decisions, and patient access depend.
Into this world, artificial intelligence has arrived with enormous promise and a credibility problem.
General-purpose GenAI tools can draft a literature summary in minutes. They can retrieve abstracts, extract data points, and synthesize findings with confidence. But ask whether that output is accurate, traceable to source documents, whether every citation was verified, or whether the methodology is reproducible and audit-ready, and the answer, for most tools, is no.
It’s easy-button-level seduction. Some internal IT teams and systems integrators are proposing AI solutions that were never designed for regulated workflows where auditability, traceability and human oversight are mandatory requirements. The distinction between AI for knowledge work and AI for regulated work is critical for life sciences. And it is why the industry needs a clear definition of Regulatory-Grade AI. A clear, fit-for-purpose definition of intent that respects copyright, that’s transparent, that doesn’t train vendors’ LLMs, and that doesn’t dangle the illusion of easy or accurate.
The emerging international consensus on AI for regulated work, reflected in guidances from the National Institute for Health and Care Excellence (NICE), Canada’s Drug Agency (CDA-AMC), the European Medicines Agency (EMA), Cochrane’s joint Position Statement on AI in Evidence Synthesis, and ISPOR’s ELEVATE, centers on four conditions: transparency in methodology, human oversight at critical decision points, traceability of AI-assisted outputs back to source, and reproducibility of methods under independent audit.
The Literature Review as a Regulatory Asset
Literature reviews are a foundational element in life sciences evidence generation.When AI enters this process, the stakes are not abstract. A missed citation in a safety review can put patient safety at risk. A hallucinated effect size in a meta-analysis can distort a cost-effectiveness model, and undocumented decisions can cause a regulatory submission to be denied.
This is why a literature review is a regulated output; AI deployed within its workflow must meet standards.
Four Principles of Regulatory-Grade AI
Drawing on the emerging consensus and our extensive experience in working with stakeholders on all sides, we see four core principles for regulatory-grade AI for literature reviews:
Principle 01: Defensibility Over Convenience
Regulatory submissions are not improved by speed alone. An AI-generated literature summary that cannot be traced to its source documents, or whose screening decisions cannot be reconstructed, is not a time-saver, it is a liability. Regulatory-grade AI produces outputs where every data point is directly linked back to its origin in the source document, a human has reviewed and approved the evidence, and where the methodology can be fully reproduced.
Principle 02: Human Expertise Embedded in the Workflow
Regulatory-grade AI is not autonomous AI. It is AI that accelerates expert judgment, surfacing relevant evidence, suggesting extractions, flagging conflicts, while keeping qualified reviewers accountable for final decisions. The expert is not removed from the loop; the loop is designed around the expert. The expert judgment becomes embedded in the audit trail.
Principle 03: Audit-Ready by Design, Not Retrofit
Regulatory submissions require complete, defensible audit trails. This means every search, every citation, every screening decision, every data extraction, and every modification must be logged with version control and timestamps. Regulatory-grade AI builds this auditability into the workflow. When a notified body or health technology assessment committee questions methodology or outputs, the answer must already exist in the system.
Principle 04: Evidence Is the Customer’s, Not the LLM Vendors
Life sciences companies handle some of the most commercially sensitive data in any industry. Unpublished clinical data, confidential evidence dossiers, scientific references subject to copyright, and proprietary analyses cannot be used to train third-party AI models. Regulatory-grade AI enforces clear data boundaries by design: customer data and copyrighted references remain the customer’s, and no confidential information is repurposed beyond the authorized workflow.
From Tasks to Evidence Assets
The first wave of AI adoption in life sciences was measured in time saved, fewer hours of screening, faster first drafts, and reduced manual extraction burden. These gains are real. But they are not the ceiling.
The deeper transformation comes when AI-supported literature reviews become organizational evidence assets: validated, centrally managed, reusable across regulatory submissions, HTA dossiers and medical affairs communications, without rework and without risks.
This is the vision behind evidence management as a strategic function. When every literature review is conducted on an regulatory-grade AI platform, the evidence is not only produced faster; it is produced once, validated properly by humans, and made available across the enterprise. The clinical evidence team’s reviews inform the health economist’s model and the medical affairs literature monitoring project.
Evidence Silos dissolve. Better decisions are made. Patients get treatments faster.
